Working… Menu

Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related Aplasia (LAMVIRE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01819792
Recruitment Status : Completed
First Posted : March 28, 2013
Last Update Posted : April 23, 2018
Information provided by (Responsible Party):
Centre Hospitalier Universitaire, Amiens

Brief Summary:
Infectious morbidity and mortality is a major complication of AML (Acute Myeloid Leukemia) induction and consolidation chemotherapies related aplasia. The main aim of this study is to measure incidence of respiratory viral infections during AML induction and consolidation chemotherapy related aplasia. Primary end point is a positive polymerase chain reaction(PCR)associated with clinical signs.

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia Other: Multiplex respiratory viral PCR Phase 4

Detailed Description:
Bacterial and fungal infection treatment is well defined with guidelines. Few data are available for viral infections and concern essentially allogeneic stem cell transplantation. These infections are associated with a high mortality and morbidity rate. Data concerning AML are essentially retrospective, pediatric and with a little number of patients. Respiratory viral infections incidence is not known. These infections may be responsible for a higher mortality rate. Different risk factors are found: age superior to 65 years, lymphopenia, co-infections. Treatment is subject to a controversy: surveillance or starting an antiviral therapy. This study aims at understanding viral infections epidemiology during long term aplasia and optimizing their management.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 119 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Incidence of Respiratory Viral Infections During AML Induction and Consolidation Chemotherapy
Study Start Date : April 2013
Actual Primary Completion Date : July 2016
Actual Study Completion Date : July 2016

Arm Intervention/treatment
patient with Acute Myeloïd Leukemia Other: Multiplex respiratory viral PCR

Primary Outcome Measures :
  1. positivity of the viral PCR in the presence of clinical signs during periods of positivity of the PCR in the presence of clinical signs [ Time Frame: at day 15 ]
    Positivity of the viral PCR in the presence of clinical signs during periods of Aplasia following chemotherapy induction and consolidation defining viral infection.

Secondary Outcome Measures :
  1. seasonal viral infection incidence measure [ Time Frame: 18 months after inclusion ]
  2. risk factor of viral infections research [ Time Frame: 18 months after inclusion ]
  3. viral infections related morbidity and mortality estimation [ Time Frame: 18 months after inclusion ]
  4. bacterial and fungal co-infection estimation [ Time Frame: 18 months after inclusion ]
  5. description of antiviral therapeutic used for treating patients [ Time Frame: 18 months after inclusion ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients over 18 years old with an AML diagnostic and treated with induction and consolidation chemotherapy. Patients enrolled in another protocol may be included.
  • Patients with relapsed leukemia who are treated with a salvage intensive therapy stay in the study
  • Patients who have signed a consent policyholder

Exclusion Criteria:

  • patients under 18 years old
  • patients treated with another treatment than induction and consolidation chemotherapy
  • pregnant women
  • patients HIV, HBV or HBC positive
  • patients with a positive PCR at J1
  • patients treated with an antiviral treatment or an immunosuppressive treatment for another pathology
  • patients under guardianship
  • Primitive immunity Deficit

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01819792

Layout table for location information
Pr Marolleau
Amiens, France, 80054
Caen, France, 14000
Chru Lille
Lille, France, 59000
Chu Rouen
Rouen, France, 76000
Sponsors and Collaborators
Centre Hospitalier Universitaire, Amiens
Layout table for investigator information
Principal Investigator: Jean Pierre MAROLLEAU, MD PHD CHU AMIENS
Principal Investigator: FABRICE JARDIN, MD PHD CHU ROUEN
Principal Investigator: OUMEDALY RENAN, MD PHD CHU CAEN
Principal Investigator: BRUNO QUESNEL, MD PHD CHRU LILLE

Layout table for additonal information
Responsible Party: Centre Hospitalier Universitaire, Amiens Identifier: NCT01819792     History of Changes
Other Study ID Numbers: PI2011_843_0005
First Posted: March 28, 2013    Key Record Dates
Last Update Posted: April 23, 2018
Last Verified: April 2018
Keywords provided by Centre Hospitalier Universitaire, Amiens:
Acute Myeloid Leukemia
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Virus Diseases
Neoplasms by Histologic Type